Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade

KRAS is a frequently mutated oncogene in lung cancer and among the most refractory to EGFR targeted therapy. Recently, preclinical evidence in pancreatic cancer has demonstrated that mutant KRAS can be regulated by EGFR. However, the distinct correlation between the EGFR/HER family members and mutan...

Descripción completa

Detalles Bibliográficos
Autores principales: Umelo, Ijeoma Adaku, De Wever, Olivier, Kronenberger, Peter, Van Deun, Jan, Noor, Alfiah, Singh, Kshitiz, Teugels, Erik, Chen, Gang, Bracke, Marc, De Grève, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652993/
https://www.ncbi.nlm.nih.gov/pubmed/25992771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652993/
https://www.ncbi.nlm.nih.gov/pubmed/25992771

Ejemplares similares